UK health cost body backs Novartis asthma drug in fresh U-turn – Chicago Tribune

UK health cost body backs Novartis asthma drug in fresh U-turn
Chicago Tribune
LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health
Life-changing jab gives hope to asthma sufferersExpress.co.uk
Asthma treatment – double U-turnWebMD.Boots.com
NICE U-turn on Novartis' Xolair for asthmaPharmaTimes
OnMedica –The Daily Telegraph –GP online
all 10 news articles »

View full post on asthma – Google News

UK health cost body backs Novartis asthma drug in fresh U-turn – Yahoo! News (blog)


Yahoo! News (blog)

UK health cost body backs Novartis asthma drug in fresh U-turn
Yahoo! News (blog)
LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health
U-turn As Asthma Drug Gets Go-aheadThe Australian
NICE U-turn over asthma drug omalizumabGP online

all 3 news articles »

View full post on asthma – Google News

UK health cost body backs Novartis asthma drug in fresh U-turn – Reuters

UK health cost body backs Novartis asthma drug in fresh U-turn
Reuters
LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health
NICE U-turn over asthma drug omalizumabGP online

all 2 news articles »

View full post on asthma – Google News